TITERS OF ANTIBODIES TO Β1-ADRENOCEPTOR AND M2 CHOLINERGIC RECEPTORS IN PATIENTS WITH VENTRICULAR ARRHYTHMIAS WITHOUT AN ORGANIC CARDIOVASCULAR DISEASE AND THEIR POSSIBLE CLINICAL SIGNIFICANCE

Aim. To identify the most promising epitopes that simulate various sites β1-adrenergic and M2-cholinergic receptors, and to evaluate their possible contribution to the development and maintenance of cardiac arrhythmias, particularly idiopathic ventricular arrhythmia. Material and methods. Patients with ventricular arrhythmias without organic cardiovascular disease (the study group; n=70) were included in the study. The control group consisted of 20 healthy volunteers. Evaluation of levels of antibodies to antigenic determinants, modeling various sites β1-adrenergic and M2-cholinergic performed in all patients. Causal treatment with clarithromycin and valacyclovir performed in part of patients. Results. Antibodies to different peptide sequences of β1-adrenergic and M2-cholinergic receptors have been identified in 25% of main group patients. A direct correlation between the frequency of episodes of ventricular tachycardia and IgG levels to MRI-MRIV (p=0.02) revealed. Increase in titre of antibodies to β1-adrenoceptors, to a peptide sequence β8 (p=0.02), and lower titers of antibodies to the M2 acetylcholine receptor — chimera MRI-MRIV IgM (p=0.06) and ARI-MRIV IgM (p=0.07) were observed when assessing the efficacy of the therapy in the causal dynamics in the group of "untreated" patients. IgG titer reduction of ARI-MRIV (p=0.02), which is 4 times out of 10 with reduction of ventricular ectopic activity , recorded after valacyclovir therapy. Clarithromycin therapy on the level of antibodies exerted no significant effect. Conclusion. Possible involvement of antibodies to β1-adrenoceptor and M2-cholinergic receptors in the development of idiopathic ventricular arrhythmias demonstrated. The relationship between the frequency of episodes of ventricular tachycardia and levels of antibody titers to M2-cholinergic receptors found. Attempt of causal treatment, depending on the possible mechanisms of the autoimmune process is executed. Further studies to confirm or refute the results to the larger sample of patients are needed.

1. Jahns R., Boivin V., Lohse M.J. Beta 1-adrenergic receptor directed autoimmunity as a cause of dilated cardiomyopathy in rats. Int J Cardiol 2006; 112: 7–14.

2. Nussinovitch U., Shoenfeld Y. Autoimmunity and heart diseases: pathogenesis and diagnostic criteria. Arch Immunol Ther Exp 2009; 57: 95–104.

3. Rodionova E.S., Mironova N.A., Aparina O.P. et al. Role of autoimmune reactions in development of cardiac arrhythmia and conduction disturbances. Ter Archiv 2012; 4: 74–78. Russian (Родионова Е.С., Миронова Н.А., Апарина О.П. и соавт. Роль аутоиммунных реакций в развитии нарушений ритма и проводимости сердца. Терапевтический архив 2012; 4: 74–78).

4. Brucato A., Maestroni S., Cumetti D. et al. Recurrent pericarditis: infectious or autoimmune? Autoimmun Rev 2008; 8: 44–47.

5. Gershwin M.E. The mosaic of autoimmunity. Autoimmun Rev 2008; 7: 161–163.

6. Stojanovich L., Marisavljevich D. Stress as a trigger of autoimmune disease. Autoimmun Rev 2008; 7: 209–213.

7. Gleicher N., Elkayam U. Peripartum cardiomyopathy, an autoimmune manifestation of allograft rejection? Autoimmun Rev 2009; 8: 384–387.

8. Zifman E., Amital H., Gilburd B., Shoenfeld Y. Antioxidants and smoking in autoimmune disease-opposing sides of the seesaw? Autoimmun Rev 2008; 8: 165–169.

9. Sitia S., Atzeni F., Sarzi-Puttini P. et al. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev 2009; 8: 281–286.

10. Gleicher N., Barad D., Weghofer A. Functional autoantibodies, a new paradigm in autoimmunity? Autoimmun Rev 2007; 7: 42–45.

11. Fritzler M.J. Challenges to the use of autoantibodies as predictors of disease onset, diagnosis and outcomes. Autoimmun Rev 2008; 7: 616–620.

12. Briani C., Samaroo D., Alaedini A. Celiac disease: from gluten to autoimmunity. Autoimmun Rev 2008; 7: 644–650.

13. Li Y., Heuser J.S., Cunningham L.C. et al. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol 2006; 177: 8234–8240.

14. Deubner N., Berliner D., Schlipp A. et al. Cardiac beta1— adrenoceptor autoantibodies in human heart disease: rationale and design of the Etiology, Titre-Course, and Survival (ETiCS) Study. Eur J Heart Fail 2010; 12: 753–762.

15. Kaya Z., Katus H.A., Rose N.R. Cardiac troponins and autoimmunity: their role in the pathogenesis of myocarditis and of heart failure. Clin Immunol 2010; 134(1):80–8.

16. Chiale P.A., Ferrari .I, Mahler E. et al. Differential profile and biochemical effects of antiautonomic membrane receptor antibodies in ventricular arrhythmias and sinus nodedysfunction. Circulation 2001; 103(13): 1765–71.

17. Baba A., Yoshikawa T., Fukuda Y. et al. Autoantibodies against M2-muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathy. Eur Heart J 2004; 25(13): 1108–15.

18. Villecco A.S., de Liberali E., Bianchi F.B., Pisi E. Antibodies to cardiac conducting tissue and abnormalities of cardiac conduction in rheumatoid arthritis. Clin Exp Immunol 1983; 53(3): 536–40.

19. Chiale P.A., Rosenbaum M.B., Elizari M.V. et al. High prevalence of antibodies against beta 1- and beta 2-adrenoceptors in patients with primary electrical cardiac abnormalities. J Am Coll Cardiol 1995; 26(4): 864–9.

20. Nussinovitch U., Shoenfeld Y. Anti-troponin autoantibodies and the cardiovascular system. Heart 2010; 96: 1518–1524.

21. Chiale P.A., Garro H.A., Schmidberg J. et al. Inappropriate sinus tachycardia may be related to an immunologic disorder involving cardiac beta adrenergic receptors. Heart Rhythm 2006; 3: 1182–1186.

22. Magnusson Y., Marullo S., Hoyer S. et al. Mapping of a functional autoimmune epitope on the beta 1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1990; 86: 1658– 1663.

23. Liu H.R., Zhao R.R., Zhi J.M. et al. Screening of serum autoantibodies to cardiac beta1-adrenocep-tors and M2- muscarinic acetylcholine receptors in 408 healthy subjects of varying ages. Autoimmunity 1999; 29: 43–51.

24. Jahns R., Boivin V., Siegmund C. et al. Activating beta-1-adrenoceptor antibodies are not associated with cardiomyopathies secondary to valvular or hypertensive heart disease. J Am Coll Cardiol 1999; 34: 1545–1551.

25. Nikolaev V.O., Boivin V., Stork S. et al. A novel fluorescence method for the rapid detection of functional beta1-adrenergic receptor autoantibodies in heart failure. J Am Coll Cardiol 2007; 50: 423–431.

26. Chiale P.A., Ferrari I., Mahler E. et al. Differential profile and biochemical effects of antiautonomic membrane receptor antibodies in ventricular arrhythmias and sinus node dysfunction. Circulation 2001; 103: 1765–1771.

27. Hoebeke J. Structural basis of autoimmunity against G protein-coupled membrane receptors. Int J Car-diol 1996; 54: 103–111.

28. Caforio A.L., Mahon N.J., Tona F., McKenna W.J. Circulating cardiac autoantibodies in dilated car-diomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail 2002; 4: 411– 417.

29. Rose N.R. Infection, mimics, and autoimmune disease. J Clin Invest 2001; 107: 943–944.

30. Eriksson U., Ricci R., Hunziker L. et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 2003; 9: 1484–1490.

31. Yoshikawa T., Baba A., Nagatomo Y. Autoimmune mechanisms underlying dilated cardiomyopathy. Circ J 2009; 73: 602–607.

32. Nagatomo Y., Yoshikawa T., Kohno T. et al. A pilot study on the role of autoantibody targeting the beta1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure. J Card Fail 2009; 15: 224–232.

33. Stork S., Boivin V., Horf R. et al. Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J 2006; 152: 697– 704.

34. Christ T., Wettwer E., Dobrev D. et al. Autoantibodies against the beta1 adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. J Mol Cell Cardiol 2001; 33: 1515–1525.

35. Sterin-Borda L., Cossio P.M., Gimeno M.F. et al. Effect of chagasic sera on the rat isolated atrial preparation: immunological, morphological and function aspects. Cardiovasc Res 1976; 10: 613–622.

36. Caforio A.L., Tona F., Bottaro S. et al. Clinical implications of anti-heart autoantibodies in myocardi-tis and dilated cardiomyopathy. Autoimmunity 2008; 41: 35–45.

37. Mobini R., Staudt A., Felix S.B. et al. Hemodynamic improvement and removal of autoantibodies against beta1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. J Autoimmun 2003; 20: 345–350.

38. Muller J., Wallukat G., Dandel M. et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000; 101: 385–391.

39. Tutor A.S., Penela P., Mayor F. Jr. Anti-beta1-adrenergic receptor autoantibodies are potent stimula-tors of the ERK1/2 pathway in cardiac cells. Cardiovasc Res 2000; 76: 51–60.

40. Hebert T.E. Anti-beta1AR antibodies in dilated cardiomyopathy: are these a new class of receptor agonists? Cardiovasc Res 2007; 76: 5–7.

41. Nussinovitch U., Katz U., Nussinovitch M. et al. Echocardiographic abnormalities in familial dysautonomia. Pediatr Cardiol 2009;30:1068–1074.

42. Lazzerini P.E., Capecchi P.L., Guideri F. et al. Autoantibody mediated cardiac arrhythmias: mechanisms and clinical implications. Basic Res Cardiol 2008; 103: 1–11.

43. Medei E., Pedrosa R.C., Benchimol Barbosa P.R. et al. Human antibodies with muscarinic activity modulate ventricular repolarization: basis for electrical disturbance. Int J Cardiol 2007; 115: 373–380.

44. Nussinovitch N., Livneh A., Katz K. et al. QT dispersion in uncomplicated familial Mediterranean fever. Clin Rheumatol 2010; 29: 1353–1356.

45. Nussinovitch U., Katz U., Nussinovitch M., Nussinovitch N. Late ventricular potentials and QT dispersion in familial dysautonomia. Pediatr Cardiol 2009; 30: 747–751.

46. Wallukat G., Nissen E., Morwinski R., Muller J. Autoantibodies against the beta- and muscarinic receptors in cardiomyopathy. Herz 2000; 25: 261–266.

47. Wallukat G., Fu H.M., Matsui S. et al. Autoantibodies against M2 muscarinic receptors in patients with cardiomyopathy display non-desensitized agonist-like effects. Life Sci 1999; 64: 465–469.

48. Wang W.Z., Zhao R.R., Wu B.W. et al. Effects of anti-peptide antibodies against human M2 muscarinic receptors on cardiac function in rats in vivo. Blood Press Suppl 1996; 3: 25–27.

49. Goin J.C., Leiros C.P., Borda E., Sterin-Borda L. Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: functional and pathological implications. FASEB J 1997; 11: 77–83.